These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23994973)

  • 1. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
    Naganuma M; Sakuraba A; Hisamatsu T; Ochiai H; Hasegawa H; Ogata H; Iwao Y; Hibi T
    Inflamm Bowel Dis; 2008 Sep; 14(9):1259-64. PubMed ID: 18393375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database.
    Bao HF; Hou CC; Ye B; Zou J; Luo D; Cai JF; Shen Y; Guan JL
    Mod Rheumatol; 2023 Jan; 33(1):207-216. PubMed ID: 34932796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
    Hibi T; Hirohata S; Kikuchi H; Tateishi U; Sato N; Ozaki K; Kondo K; Ishigatsubo Y
    Medicine (Baltimore); 2016 Jun; 95(24):e3863. PubMed ID: 27310969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
    Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
    Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.
    Lee JH; Cheon JH; Jeon SW; Ye BD; Yang SK; Kim YH; Lee KM; Im JP; Kim JS; Lee CK; Kim HJ; Kim EY; Kim KO; Jang BI; Kim WH
    Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
    Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J; Ji DN; Shen Y; Guan JL; Zheng SB
    Ann Clin Lab Sci; 2017 Mar; 47(2):171-177. PubMed ID: 28442519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
    Hisamatsu T; Ueno F; Matsumoto T; Kobayashi K; Koganei K; Kunisaki R; Hirai F; Nagahori M; Matsushita M; Kobayashi K; Kishimoto M; Takeno M; Tanaka M; Inoue N; Hibi T
    J Gastroenterol; 2014 Jan; 49(1):156-62. PubMed ID: 23955155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature.
    Toyonaga T; Nakase H; Matsuura M; Minami N; Yamada S; Honzawa Y; Hukata N; Yoshino T; Chiba T; Okazaki K
    Digestion; 2013; 88(4):217-21. PubMed ID: 24247154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of patients with intestinal Behçet's disease requiring treatment with immunosuppressants or anti-TNFα antibody.
    Kimura Y; Asako K; Kikuchi H; Kono H
    Mod Rheumatol; 2016; 26(1):132-7. PubMed ID: 26025434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
    Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
    Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study.
    Barreiro-de Acosta M; García-Bosch O; Souto R; Mañosa M; Miranda J; García-Sanchez V; Gordillo J; Chacon S; Loras C; Carpio D; Maroto N; Menchén L; Rojas-Feria M; Sierra M; Villoria A; Marin-Jimenez I;
    Inflamm Bowel Dis; 2012 May; 18(5):812-7. PubMed ID: 21826765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL; Atienza-Mateo B; Calvo-Rio V; Beltrán E; Sánchez-Bursón J; Adán A; Hernández-Garfella M; Valls-Pascual E; Sellas-Fernández A; Ortego N; Maíz O; Torre I; Fernández-Espartero C; Jovani V; Peiteado D; Valle DD; Aurrecoechea E; Caracuel MA; García-González AJ; Álvarez ER; Vegas-Revenga N; Demetrio-Pablo R; Castañeda S; González-Gay MA; Hernández JL; Blanco R;
    J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.